Mir-634 Exhibits Anti-Tumor Activities Toward Hepatocellular Carcinoma Via Rab1a and Dhx33

Chris Zhiyi Zhang,Yun Cao,Jia Fu,Jing-Ping Yun,Mei-Fang Zhang
DOI: https://doi.org/10.1016/j.molonc.2016.09.001
2016-01-01
Molecular Oncology
Abstract:Deregulation of microRNAs contributes to the aberrant growth of hepatocellular carcinoma (HCC). Here, we showed that miR-634 expression was frequently decreased in HCC. Low miR-634 expression was significantly associated with larger tumor size, poorer tumor differentiation, advanced TNM stage, vascular invasion, absence of tumor capsule and unfavorable overall survival. Overexpression of miR-634 markedly attenuated cell viability, colony formation, tumor growth and metastasis, whereas miR-634 inhibition resulted in the opposite phenotypes. Furthermore, re-introduction of miR-634 induced cell apoptosis in vitro and in vivo. Mechanistically, miR-634 inhibited the expression of Rab1A and DHX33 via directly binding to the 3'-UTR of both genes. In clinical samples, the expression of Rab1A or DHX33 was reversely correlated with miR-634. Re-expression of Rab1A or DHX33 abrogated the miR-634-mediated inhibition of cell proliferation and migration. Collectively, our data suggest a tumor suppressor role of miR-634 in HCC. The newly identified miR-634/Rab1A or miR-634/DHX33 axis serves as a potential therapeutic target for the clinical management. (C) 2016 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
What problem does this paper attempt to address?